Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Gynecologic 1Breast 1

Conditions

Colorectal Neoplasms 142Stomach Neoplasms 104Carcinoma, Non-Small-Cell Lung 87Pancreatic Neoplasms 81Carcinoma, Hepatocellular 74Melanoma 59Esophageal Neoplasms 57Ovarian Neoplasms 50Squamous Cell Carcinoma of Head and Neck 49Parkinson Disease 4, Autosomal Dominant Lewy Body 44Neoplasms 43Carcinoma, Renal Cell 43Triple Negative Breast Neoplasms 39Neoplasm Metastasis 37Lung Neoplasms 36Breast Neoplasms 36Uterine Cervical Neoplasms 35Cholangiocarcinoma 35Esophageal Squamous Cell Carcinoma 33Head and Neck Neoplasms 29Endometrial Neoplasms 29Biliary Tract Neoplasms 26Carcinoma, Transitional Cell 25Urinary Bladder Neoplasms 23Colonic Neoplasms 23Small Cell Lung Carcinoma 20Prostatic Neoplasms 17Liver Neoplasms 17Adenocarcinoma Of Esophagus 15Adenocarcinoma 15

Interventions

pembrolizumab 4Nivolumab 3sintilimab 2Oxaliplatin 2Leucovorin 2Fluorouracil 2Bevacizumab 2vicriviroc 1trifluridine tipiracil drug combination 1spartalizumab 1relatlimab 1regorafenib 1epacadostat 1dabrafenib 1copanlisib 1binimetinib 1atezolizumab 1Tiragolumab 1Irinotecan 1Immune Checkpoint Inhibitors 1Fulvestrant 1E7046 1Cetuximab 1Capecitabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Spinocerebellar Degenerations × pembrolizumab × Gastrointestinal × Clear all
NCT03374254 2024-11-21

KEYNOTE-651

Merck Sharp & Dohme LLC

Phase 1 Completed
116 enrolled 18 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT03631407 2024-11-21

MK-7690-046

Merck Sharp & Dohme LLC

Phase 2 Completed
41 enrolled 20 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT04432857 2024-06-27

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Active not recruiting
63 enrolled
BreastGastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Spinocerebellar Degenerations, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03182894 2018-08-28

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer

University of Pittsburgh

Phase 1/2 Withdrawn
Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡